February Grants — April 2010
Adinoff, B., NIH, Clinical Trials Network: North Texas Node, $650,868 (supplement); Adinoff, B., NIH, Stress, HPA Axis Dysfunction, and Relapse in Alcoholism, $233,795; Barton, T., TDSHS, Human Immunodeficiency Virus Perinatal Prevention, $56,843; Bibb, J., NIH, The Regulation of Dopamine Neurotransmission by CDK5, $281,000; Burgess, S., NIH, Factors Controlling Metabolic Flux in the Liver by NMR Isotopomer Analysis, $180,000.
Castrillon, D., NIH, Mouse Models and Translational Studies of Endometrial Cancer, $207,500; Chen, C., NIH, Asymmetric Synthesis of Biologically Active Marine Natural Products, $182,712 (supplement); Chen, C., NIH, Asymmetric Synthesis of Biologically Active Marine Natural Products, $169,290; Cobb, M., NIH, Regulation and Function of ste20-Related Protein Kinases, $295,773; Elliott J., NIH, Mechanisms of SOD1 Toxicity in ALS, $17,718.
Elmquist, J., NIH, Leptin Action and Central Melanocortin Systems, $198,891; Elmquist, J., NIH, Leptin Action and Central Melanocortin Systems, $198,891; Emslie, G., NIH, Pediatric MDD: Sequential Treatment with Fluoxetine and Relapse Prevention CBT, $371,579; Gao, F., UTHSC San Antonio, Development of Body-Powered Prosthetic Simulator, $5,000; Goodman, J., NIH, A Simple Cellular Model for Lipodystrophy, $31,500 (supplement).
Greene, R., NIH, Dopamine Modulation of NMDA Receptor Synaptic Responses; $20,250; Grinnell, F., NIH, Development of an In Vitro Wound Healing Model, $83,989 (supplement); Hansen, E., NIH, Haemophilus ducreyi Inhibits Phagocytosis, $235,757; Hobbs, H., NIH, Role of ABCG5 and ABCG8 in Sterol Metabolism, $271,097; Igarashi, P., NIH, Regulation of Kidney-Specific Gene Expression, $193,122.
Jin, E., NIH, Role of Excess Glycogenolysis in Fasting Hyperglycemia in Obesity-Associated T2DM, $81,764; Johnson, J., NIH, Regulation and Function of Ascl1 (Mash1) in Neural Development, $23,266; Karandikar, N., NIH, Dissecting the Immune Basis of Disease and Therapy, $169,004; Karandikar, N., NIH, Role of T Cells in the Immune Modulation of MS, $250,625; Lu, H., NIH, Quantitative Measurement of Spinal Cord Perfusion in Humans Using MRI, $159,242.
Lum, L., NIH, Hedgehog Signal Transduction Across the Cell Membrane, $185,049; MacDonald, R., NIH, Determining the Developmental Progression of PTF1 Targets by ChiP-Seq, $11,250; McPhaul, M., NIH, R. L. Kirschstein T-35 to support NHLBI-Focused Short-Term Predoctoral Training, $37,013; Medin, P., NIH, Spinal Cord Tolerance to Radiosurgical Dose Delivery, $222,299; McClung, C., NIH, Role of the Circadian Clock in the Development and Treatment of Mood Disorders, $25,000.
Monteggia, L., NIH, MeCP2-Dependent Transcriptional Repression and Neurotransmission, $225,000; Muallem, S., NIH, Signaling Mechanisms in Salivary Gland Cells, $237,435; Norgard, M., NIH, The RpoN-Rp0S Regulatory Pathway in Borrelia Burgdorferi, $250,000; Pfeiffer, J., NIH, The Influence of Host Barriers on Viral Quasispecies Diversity and Pathogenesis, $198,000; Powell, C., NIH, Neuroligin Function in Vivo: Implications for Autism and Mental Retardation, $25,000.
Ross, E., NIH, G Protein-Coupled Receptors – Structure and Regulation, $242,550; Russell, D., NIH, Mouse Phenotype Core, Project 9 and 10, $99,875 (supplement); Savani, R., NIH, ABCA3 and the Response to Lung Injury, $250,000; Self, D., NIH, Mechanisms of Altered Dopamine Signaling in Cocaine Addiction, $222,750; Skinner, C., NIH, Facilitating Risk-Appropriate Colorectal Cancer Testing, $2,000 (supplement).
Smiraldo, P., NIH, T-loop Dynamics During Tlomerase Inhibition Chemotherapy, $52,154; Souza, R., NIH, Basic and Clinical Studies on the Role of Bile Acids in Barrett’s Esophagus, $207,500; Uyeda, K., NIH, Carbohydrate Regulation of Hepatic Gene Expression, $150,000; Velez, N., NIH, Targeting Trypanosoma brucei S-Adenosylmethionine Decarboxylase in Drug Discovery, $28,740; Yarovinsky, F., NIH, Cellular and Molecular Mechanisms of Host Resistance to Toxoplasma Gondii, $250,000; Zoltowski, B., NIH, Structural Dynamics of Pas Domain Containing Transcription Factors, $47,606.
Courtney, A., NIH/Univ. of California, Los Angeles, A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting MS, $5,000; Devous, M., NIH/UTDallas, Supplement to Neuroimaging of Dedifferentiation and Memory Across the Lifespan, $127,714; Falck, J., NIH/Medical College of Wisconsin, Cytochrome P450 Eicosanoids and Myocardial Injury, $15,018; Frohman, E., NIH/Univ. of Pennsylvania, Novel Clinical and Ocular Imaging Outcomes With Long-Term Follow-up in MS, $120,530; Gruchalla, R., NIH/Univ. of Wisconsin-Madison, Inner City Asthma Consortium (ICAC): Immunologic Approaches to Reduce Asthma, $287,452.
Hall, C., NIH/Univ. of Cincinnati, Recanalization Therapies and Markers of Stroke Outcomes STOP-IT, $14,442; Lee, J., NIH/UTHSC-Houston, A Pilot Study to Determine the Safety of Argatroban Injection in Combination With TPA, $55,521; Margraf, L., NIH/CureSearch- NCCF, Cancer Therapy Evaluation Program, $4,465; Norgard, M., NIH/UTMB Galveston, Region VI Center for Biodefense and Emerging Infections RP 008, $178,501; Rogers, Z., NIH/Thomas Jefferson Univ., Basic and Translational Research Program in Sickle Cell Disease, $1,389.
Scherer, P., NIH/Cincinnati Children’s Hospital Medical Center, Adiponectin and Cardiovascular Disease in the CKiD Children, $48,657; Seikaly, M., NIH/The Children’s Mercy Hospital, Chronic Kidney Disease in Children (CKid), $3,968; Szmuk, P., DHHS/ Children’s Hospital Boston, Assessment of Long-Term Neurodevelopmental Outcomes in Pediatric Patients Administered Regional and General Anesthesia as Neonates or Infants, $9,524; Vernino, S., NIH/ Mayo Clinic Rochester, Autonomic Disorders Programs Project, $10,184.
Brown, E.S., Stanley Medical Research Inst., A Randomized, Double-Blind, Placebo Controlled Trial of Pregnenolone for Bipolar Depression, $165,011; Mineo, C., American Diabetes Assn., Role of Pentraxins and Endothelial Fogamma Receptor IIB in High-Fat-Diet-Induced Insulin Resistance, $90,000; Roehrborn, C., Egyptian Cultural & Educational Bureau, Molecular Changes in Bladder Carcinoma: An Alternative to Classic Prognostic Indicators, $10,000.
Scherer, P., Albert Einstein College of Medicine, Identification of Adipocyte Cells in Adipose Tissue Turnover and Obesity, $50,000; Wan, Y., March of Dimes Birth Defects Fndtn., Maternal PPAR-Gamma in Lactation and Neonate Health, $68,182; Word, R., Amer. Urogynecologic Society, Recovery of the Anal Sphincter Complex for Birth Trauma: The Role of Mesenchymal Stem Cells, $15,000 (Pathi S., fellow); Wu, J., March of Dimes Birth Defects Fndtn., Chromatin Regulation of Sonic Hedgehog Signaling Pathway, $68,182.
Industry-Sponsored Awards, dollar amounts not available
Anderson, Jr., L., An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK-0683) or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma; Batra, P., Advanced Applications of Intraoperative Volume CT Scanner for Endoscopic Sinonasal and Skull Base Surgery; Carr, B., A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of a Combination Oral Contraceptive Regimen (DR-103) for the Prevention of Pregnancy in Women.
Gerber, D., A Phase I/II Study of Erlotinib and Romidepsin in Advanced Non-Small-Cell Lung Cancer; Kenkel, J., A Multicenter, Single-Blind, Randomized, “No-Treatment” Control, Study of the Safety and Effectiveness of Juvéderm Voluma XC Injectable Gel for Cheek Augmentation to Correct Age-Related Volume Deficit in the Mid-Face; Neunert, C., An Open Label Study Evaluating the Safety and Efficacy of Long-Term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura (ITP).
O’Suilleabhain, P., A Study to Evaluate the Safety and Efficacy of IPX066 in Advanced Parkinson’s Disease; Ramos-Roman, M., A Trial Comparing Efficacy and Safety of NN5402 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes; Rockey, D., A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of HPN-100 for Maintaining Remission in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy (HALT-HE).
Rosenberg, R., A Phase 3 Extension, Multicenter, Double-Blind, Long Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer’s Disease Who Participated in Study ELN115727-301 or in Study ELN115727-302; Sánchez, P., A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of Pagibaximab Injection in Very-Low-Birth-Weight Neonates for the Prevention of Staphylococcal Sepsis; Saxena, R., Evaluation of Monthly Darbepoetin alfa Dosing for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis: An Active-Controlled, Double-Blind Study.
Sharifi, N., A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients With Progressive, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy; Vazquez, M., A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism